Migraine is a complex, serious, debilitating neurological disease that most commonly occurs between the ages of 30 to 49, impacting people during the formative and most productive years of their life.1-4

Over 90% of people with migraine are impaired during a migraine attack, and more than 50% reported severe impairment, or required bed rest.3

Migraine may cause productivity loss. People with migraine lose on average 9 more workdays annually than those without migraine.5

This page contains private content that is only available for registered users. Please log in if you are already registered, or create an account to gain access to the Working With MigraineTM program content.

REGISTER

LOG IN WITH LinkedIn

Working With MigraineTM Program Overview

This turnkey program is available free of charge and is specifically built to help employers empower those with migraine to take steps to better understand and manage migraine. All the materials and content necessary for implementation can be found on this website.

Program components include:

  • Program implementation guide with step-by-step instructions to get you started
  • Set-up materials to raise awareness within your organization
  • Educational presentations/videos for employees on key migraine topics, including:
    • Session 1: Migraine Basics
    • Session 2: Migraine Triggers
    • Session 3: Migraine Treatment Landscape
    • Session 4: Migraine Well-being and Self-Management
  • Practical resources to help employees manage migraine
  • Feedback tools to assess the program's success and assure continued improvement

Do you know the economic burden of migraine on your organization?

The Employer Migraine Cost Estimator is an interactive calculator to help estimate the economic impact of migraine on your organization.
Learn more.

Linkedln is a registered trademark of Linkedln Corporation and its affiliates in the United States and/or other countries.

References: 1. Russo AF. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 2. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553-622. 3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349. 4. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-6629. 5. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization costs among migraine patients in the United States. Headache. 2018;58:700-714.

© 2019, 2020 Amgen Inc. All rights reserved.
www.amgen.com